−4,29 %
−2,19 %
−25,97 %
−75,67 %
−76,41 %
−83,90 %
−96,34 %
−99,79 %
−97,59 %
ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34%. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.
Lue lisääMarkkina-arvo
31,82 milj. SEK
Vaihto
66,05 t. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
